Columbia Initiative in Cell Engineering and Therapy
Columbia Initiative in Cell Engineering and Therapy
Cell-based therapies hold great promise for the future of medicine. From cancer and inherited disorders to autoimmune and degenerative diseases, engineered cells utilized as living drugs, including CAR T therapy, offer unprecedented therapeutic potential to alleviate or cure conditions once considered untreatable.
The Columbia Initiative in Cell Engineering and Therapy (CICET) is a university-wide academic endeavor to advance transformative cell and gene therapies. Harnessing Columbia’s collective excellence across the Vagelos College of Physicians and Surgeons, the School of Engineering and Applied Sciences, the Faculty of Arts and Sciences, and in partnership with NewYork-Presbyterian Hospital, CICET unites discovery science with clinical translation.
News and Announcements
- June 16, 2026
The prize honors Sadelain's development of chimeric antigen receptor T-cell (CAR-T) therapies, which have revolutionized treatment for blood cancers and solid tumors.
Topic
- March 3, 2026
This month’s Researcher of the Month spotlights Michel Sadelain, highlighting his groundbreaking contributions to cancer immunotherapy and his passion for advancing scientific discovery at Columbia.
- February 26, 2026
HIT cells—a close cousin to CAR-T cells—eradicate kidney, pancreatic, and ovarian cancers in mice and could remove a major impediment to cell therapy against many solid tumors.
- February 11, 2026
Cell therapy pioneer has been awarded a prize for revolutionizing cancer treatment with personalized immunotherapy developed from a patient’s own cells.
Topic
Events
There are currently no upcoming events.